Results 1 to 10 of about 3,125,328 (279)

Insights into gemcitabine resistance in pancreatic cancer: association with metabolic reprogramming and TP53 pathogenicity in patient derived xenografts [PDF]

Journal of Translational Medicine
Background With poor prognosis and high mortality, pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies. Standard of care therapies for PDAC have included gemcitabine for the past three decades, although resistance often ...
Mariam M. Konaté, Julia Krushkal, Ming-Chung Li, Li Chen, Yuri Kotliarov, Alida Palmisano, Rini Pauly, Qian Xie, P. Mickey Williams, Lisa M. McShane, Yingdong Zhao   +10 more
doaj   +3 more sources

METTL3 enhances pancreatic ductal adenocarcinoma progression and gemcitabine resistance through modifying DDX23 mRNA N6 adenosine methylation [PDF]

Cell Death and Disease, 2023
The aim of the present study was to clarify the mechanism of how METTL3 regulated pancreatic ductal adenocarcinoma (PDAC) progression by m6A modification of its downstream target mRNA and signaling pathway.
Che-Chung Lin, Ting Li, Yan Wang, Shihui Lai, Yue Huang, Zhenyun Guo, Xiang Zhang, S. Weng   +7 more
semanticscholar   +2 more sources

Hsa-miR-3178/RhoB/PI3K/Akt, a novel signaling pathway regulates ABC transporters to reverse gemcitabine resistance in pancreatic cancer

Molecular Cancer, 2022
Background Although gemcitabine has been considered as the first-line drug for advanced pancreatic cancer (PC), development of resistance to gemcitabine severely limits the effectiveness of this chemotherapy, and the underlying mechanism of gemcitabine ...
Jianyou Gu, Wenjie Huang, Xianxing Wang, Junfeng Zhang, Tian Tao, Yao Zheng, Songsong Liu, Jiali Yang, Zhe-Sheng Chen, Chao-Yun Cai, Jinsui Li, Huaizhi Wang, Yingfang Fan   +12 more
doaj   +2 more sources

Molecular Mechanisms of Gemcitabine Resistance in Cholangiocarcinoma. [PDF]

Oncol Res
Cholangiocarcinoma (CCA) is an aggressive cancer originating from bile duct epithelium. Surgical resection remains the primary curative treatment for CCA.
Kidoikhammouan S, Saengboonmee C, Wongkham S, Seubwai W.   +3 more
europepmc   +2 more sources

m6A eraser FTO impairs gemcitabine resistance in pancreatic cancer through influencing NEDD4 mRNA stability by regulating the PTEN/PI3K/AKT pathway

Journal of Experimental & Clinical Cancer Research, 2023
Background Gemcitabine resistance has brought great challenges to the treatment of pancreatic cancer. The N6-methyladenosine (m6A) mutation has been shown to have a significant regulatory role in chemosensitivity; however, it is not apparent whether ...
Kai Lin, Endi Zhou, Ting Shi, Siqing Zhang, Jinfan Zhang, Ziruo Zheng, Yuetian Pan, Wentao Gao, Yabin Yu   +8 more
doaj   +2 more sources

Nuclear PLD1 combined with NPM1 induces gemcitabine resistance through tumorigenic IL7R in pancreatic adenocarcinoma

Cancer Biology & Medicine, 2023
Objective: Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant gastrointestinal cancer with a 5-year survival rate of only 9%. Of PDAC patients, 15%-20% are eligible for radical surgery.
Danqi Fu, Jingrui Yan, Zhaoyu Zhang, Yang Liu, Xiaoqing Ma, Jinsheng Ding, Shengyu Yang, Ran Zhao, Antao Chang, Chuntao Gao, Jing Liu, Tiansuo Zhao, Xiuchao Wang, Chongbiao Huang, Song Gao, Ying Ma, Bo Tang, Yukuan Feng, Hongwei Wang, Jihui Hao   +19 more
doaj   +2 more sources

Histone acetyltransferase 1 promotes gemcitabine resistance by regulating the PVT1/EZH2 complex in pancreatic cancer

Cell Death and Disease, 2021
The poor prognosis of pancreatic cancer is primarily due to the development of resistance to therapies, including gemcitabine. The long noncoding RNA PVT1 (lncRNA PVT1) has been shown to interact with enhancer of zeste 2 polycomb repressive complex 2 ...
Yan Sun, Dianyun Ren, Yingke Zhou, Jian Shen, Heshui Wu, Xin Jin   +5 more
doaj   +2 more sources

Targeting ketone body metabolism in mitigating gemcitabine resistance. [PDF]

JCI Insight
Chemotherapy is often combined with surgery for muscle invasive and nonmuscle invasive bladder cancer (BCa). However, 70% of the patients recur within 5 years. Metabolic reprogramming is an emerging hallmark in cancer chemoresistance.
Rohena-Rivera K, You S, Kim M, Billet S, Ten Hoeve J, Gonzales G, Huang C, Heard A, Chan KS, Bhowmick NA.   +9 more
europepmc   +2 more sources

RRP9 promotes gemcitabine resistance in pancreatic cancer via activating AKT signaling pathway [PDF]

Cell Communication and Signaling, 2022
Background Pancreatic cancer (PC) is a highly lethal malignancy regarding digestive system, which is the fourth leading factor of cancer-related mortalities in the globe. Prognosis is poor due to diagnosis at advanced disease stage, low rates of surgical
Zhiqi Zhang, Haitao Yu, Wenyan Yao, Na Zhu, Ran Miao, Zhiquan Liu, Xuwei Song, Chunhua Xue, Cheng-Cai Cai, Ming Cheng, Ke Lin, Dachuan Qi   +11 more
semanticscholar   +2 more sources

Long non-coding RNA LINC00665 promotes gemcitabine resistance of Cholangiocarcinoma cells via regulating EMT and stemness properties through miR-424-5p/BCL9L axis

Cell Death and Disease, 2021
Gemcitabine is the first-line chemotherapy drug for cholangiocarcinoma (CCA), but acquired resistance has been frequently observed in CCA patients. To search for potential long noncoding RNAs (lncRNAs) involved in gemcitabine resistance, two gemcitabine ...
Min Lu, Xinglei Qin, Yajun Zhou, Gang Li, Zhaoyang Liu, Xiwen Geng, Haodi Yue   +6 more
doaj   +2 more sources